Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Journal Title: Pharmacological Reports - Year 2013, Vol 65, Issue 4
Abstract
Combination with suitable pharmacological agents can improve the antiobesity and antidiabetic actions of glucagon like peptide-1 (GLP-1) based therapies. GLP-1 agonist exendin-4 may have insulin-independent effects on amelioration of insulin resistance and hepatic steatosis by virtue of its action on hepatic GLP-1 receptors, and these effects can be improved by combination with proton pump inhibitors. However, it was not assessed whether omeprazole can improve the peripheral actions of exendin-4 in the state of insulin deficiency.
Authors and Affiliations
Vishal Patel, Amit Joharapurkar, Nirav Dhanesha, Samadhan Kshirsagar, Jaysukh Detroja, Kartikkumar Patel, Tejal Gandhi, Kirti Patel, Rajesh Bahekar, Mukul Jain
Keywords
Related Articles
- EP ID EP93869
- DOI -
- Views 91
- Downloads 0
Progesterone therapy in women with epilepsy.
Background: Progesterone with its anti-seizure effect plays a role in the pathophysiology of catamenial epilepsy which affects 31-60% of epileptic women. In this study, an attempt to treat women suffering from catamenial...
Cytokines, prostaglandins and nitric oxide in the regulation of stress-response systems.
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is accepted as one of the fundamental biological mechanisms that underlie major depression. This hyperactivity is caused by diminished feedback inhibition of...
Novel I(1)-imidazoline S43126 enhance insulin action in PC12 cells.
The I(1)-imidazoline receptor is a novel target for drug development for hypertension and insulin resistance, major disorders associated with type 2 diabetes. In the present study, we examined the effects of a novel imid...
Treatment of dyslipidemia in patients with diabetes mellitus.
The article reviews the key aspects of pathophysiology of diabetic dyslipidemia, its treatment and associated risk of cardiovascular complications. It examines the difference in lipidmetabolism between type 1 and type 2...
Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats.
Previous studies proved that food strongly enhanced the bioavailability of vinpocetine. Food may change the pharmacokinetics of a drug by affecting various factors, including gastrointestinal pH. However, the influence o...